AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan (Dato-DXd) receives EMA validation for lung and breast cancer treatments, advancing the potential for improved patient outcomes...

AstraZeneca's Voydeya for PNH patients is recommended for EU approval. Learn about this promising treatment and its potential benefits for patients...

AstraZeneca's Tagrisso approved in the US for EGFRm non-small cell lung cancer with chemotherapy. FLAURA2 trial results show significant benefit...

AstraZeneca reports strong FY and Q4 2023 results, with revenue growth, new medicine approvals, and optimistic growth projections for 2024...